Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biosense Webster Inc

http://www.biosensewebster.com

Latest From Biosense Webster Inc

Minute Insight: Trials Sponsored By Medtronic and Biosense Webster Show Benefits Of AFib Ablation

Results from two industry-supported clinical trials published in the last week offer more support for treating atrial fibrillation with catheter ablation rather than medication alone.

Minute Insights Clinical Trials

J&J Pumps MedTech Growth; Offers $16.6BN+ For Abiomed

Johnson & Johnson plans to buy Abiomed for $380 per share – about $16.6bn in total – plus up to $35 per share in potential commercial and clinical milestone-contingent payments. Abiomed is the clear leader in percutaneous circulatory support technology, but would benefit from J&J's reach and resources while complementing J&J's Biosense Webster electrophysiology business.

Approvals Commercial

Exec Chat: Biosense Webster Is Ready For Next Chapters Of The Electrophysiology Story (Part II)

In Part II of Medtech Insight’s extensive interview, Michael Bodner, the worldwide president of Johnson & Johnson/Biosense Webster, talked about the company’s vision for electrophysiology beyond the first generation of pulsed field ablation and the company’s commitment to improving diversity and inclusion.

Exec Chats Diversity & Inclusion

Exec Chat: Biosense Webster Is Ready For Next Chapters Of The Electrophysiology Story

Medtech Insight talked to Michael Bodner, the worldwide president of Johnson & Johnson/Biosense Webster, about the company’s plans to stay number one in the cardiac ablation market. In part 1 of the interview, the medtech veteran talked about the company's plan to compete in the crowded pulsed field ablation field.

Exec Chats Cardiovascular
See All

Company Information

  • Industry
  • Medical Devices
    • Diagnostic Imaging Equipment & Supplies
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
UsernamePublicRestriction

Register